Business Wire

CSG and NetLync Drive MNO and MVNO eSIM Transformation

29.4.2025 09:30:00 CEST | Business Wire | Press Release

Share

With eSIM set to become the standard for all new phones this year,mobile network operators (MNOs) and mobile virtual network operators (MVNOs) face mounting pressure to modernize their entitlement infrastructure. To address this market need, CSG® (NASDAQ: CSGS) today announced a new partnership with leading entitlement server provider NetLync and launched CSG Entitlements-as-a-Service, powered by NetLync. This new SaaS platform gives operators the speed and agility they need to power seamless iOS and Android experiences in weeks, not months. It helps them stay competitive in an eSIM-only future and avoid the high costs of building and managing their own entitlement infrastructure.

“The shift to eSIM-only devices drives a major change in the telecommunications industry that will redefine user experiences,” said Chad Dunavant, Chief Product & Strategy Officer, CSG. “This evolution creates an exciting opportunity for early movers to spark disruption and unlock powerful new revenue streams. That’s why CSG partnered with NetLync—to combine our strengths and make it easier for MNOs and MVNOs to meet the rising demand for eSIM services and simplify the process of managing entitlements. CSG Entitlements-as-a-Service, powered by NetLync, will help them save time and resources, launch new services faster and provide a customer experience that builds lasting loyalty.”

Combining CSG and NetLync’s strengths in this platform marks a turning point for MNOs and MVNOs, who have long struggled with complex, fragmented entitlement systems. Built for speed and simplicity, CSG Entitlements-as-a-Service, powered by NetLync, removes the roadblocks of legacy infrastructure and enables operators to scale with ease, instantly roll out new features and deliver smoother onboarding. For subscribers, the result is fewer service delays, faster device setup and instant access to the latest features, which, in turn, drives their trust and loyalty.

“NetLync’s partnership with CSG gives MNOs and MVNOs a powerful solution to embrace the shift to eSIM,” said Emir Aboulhosn, CEO & Co-Founder, NetLync. “With CSG Entitlements-as-a-Service, powered by NetLync, operators can leapfrog the limitations of outdated entitlement systems and accelerate their path to scalability and innovation. This platform empowers them to deliver experiences that meet today's eSIM demands and enhanced OEM features, positioning them for long-term success in a rapidly evolving digital landscape.”

Get the facts on CSG Entitlements-as-a-Service, powered by NetLync, and read our blog or watch this interview on how you can tune your business for an eSIM-only future.

About CSG
CSG empowers companies to build unforgettable experiences, making it easier for people and businesses to connect with, use and pay for the services they value most. Our customer experience, billing and payments solutions help companies of any size make money and make a difference. With our SaaS solutions, company leaders can take control of their future and tap into guidance along the way from our fiercely committed and forward-thinking CSGers around the world.

Want to be future-ready and a change-maker like the global brands that trust CSG? Visit csgi.com to learn more.

About NetLync
NetLync, led by a dedicated team of telecom industry experts, collaborates closely with OEMs, successfully launching Entitlements-as-a-Service® that gets MNOs and MVNOs up and running with enhanced cellular features at little cost. Headquartered in Dublin, with offices in London and Vancouver, NetLync addresses challenges faced by carriers and OEMs, preparing for the upcoming era of digital acquisition and onboarding.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250429149805/en/

Contacts

CSG Contacts:
Kristine Østergaard
Public Relations
+44 (0)79 2047 7204
kristine.ostergaard@csgi.com

John Rea
Investor Relations
+1 (210) 687-4409
john.rea@csgi.com

Davis Barker
Investor Relations
+1 (303) 884-4506
davis.barker@csgi.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye